Senseonics Holdings (SENS) AI Stock Analysis

• Market Cap: $264.82M
• Dividend Yield: N/A
• Average Volume (3M): 547.93K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.96
• Revenue Growth: 31.94%
• EPS Growth: 36.59%
• Country: US
• Employees: 117
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Devices
• EPS (TTM): -0.46
• Shares Outstanding: 41,770,466
• 10 Day Avg. Volume: 720,022
• 30 Day Avg. Volume: 547,932
• PEG Ratio: 0.10
• Price to Book (P/B): 3.77
• Price to Sales (P/S): 6.53
• P/FCF Ratio: -3.82
• Enterprise Value/Market Cap: 1.01
• Enterprise Value/Revenue: 7.23
• Enterprise Value/Gross Profit: 16.09
• Enterprise Value/Ebitda: -4.99
• 1Y Price Target: $18.70
• Price Target Upside: 194.95% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 7
• EPS Forecast (FY): -2.81
• Revenue Forecast (FY): $60.07M

• Rating: 51 Neutral
• Price Target: $6.50 ▲(2.52% Upside)
• Action: Reiterated Date: 03/13/26
• Date: Action: Reiterated 03/13/26

The score is held back primarily by weak financial performance—large ongoing losses and persistent cash burn—despite improving revenue growth and margins. Earnings-call guidance and operational progress provide the main support, while bearish technicals (below major moving averages with negative MACD) add near-term risk; valuation is hard to anchor due to negative earnings and no dividend.

Positive Factors

Reaccelerating revenue and patient growth

Sustained top-line momentum and rapid patient adoption point to expanding product-market fit for Eversense. Doubling the U.S. patient base and strong new patient starts create a larger recurring-revenue pool and provider familiarity that should support multi-quarter revenue expansion as commercialization scales.

Material and durable gross margin improvement

Transition to higher gross margins signals improving unit economics from sensor and transmitter sales plus consignment/recurring consumables. Margin expansion creates structural leverage: as installed base grows, incremental revenue converts to profit more quickly, supporting sustainable operating improvements over quarters.

Internalized commercialization and strategic partnerships

Bringing U.S. and selected EU commercial assets in-house and securing CE mark plus pump integration increases control of go-to-market, revenue recognition, and customer experience. This reduces partner dependency, aligns incentives for DTC/prescriber efforts, and supports more cohesive long-term scaling and international expansion.

Negative Factors

Persistent negative operating and free cash flow

Chronic negative operating and free cash flow means the business remains reliant on external financing until scale-based profitability materializes. Continued cash burn limits optionality, increases refinancing risk, and forces management to prioritize capital allocation around near-term growth that must convert to sustainable cash generation.

Large planned 2026 operating spend and cash utilization

An intentionally heavy 2026 cost base to build in-house commercial capabilities dramatically increases near-term losses and execution risk. The large incremental SG&A and DTC investments must deliver durable patient retention and conversion; otherwise, the company could face elevated cash burn and financing pressure over multiple quarters.

Balance-sheet volatility and prior negative equity periods

Historical negative equity and prior dilution signal recurring capital raises and balance-sheet instability. Even with more manageable leverage today, this track record increases the likelihood of future dilution or higher-cost financing if operating losses persist, creating a structural funding and governance headwind.

Senseonics Holdings Business Overview & Revenue Model

Company Description

Senseonics Holdings, Inc., a medical technology company, develops and commercializes continuous glucose monitoring (CGM) systems for people with diabetes in the United States, Europe, the Middle East, and Africa. The company's products include Eversense and Eversense XL, which are implantable CGM systems to measure glucose levels in people with diabetes through an under-the-skin sensor, a removable and rechargeable smart transmitter, and a convenient app for real-time diabetes monitoring and management for a period of up to six months. It serves healthcare providers and patients through a network of distributors and strategic fulfillment partners. The company has a collaboration agreement with the University Hospitals Accountable Care Organization. Senseonics Holdings, Inc. was founded in 1996 and is headquartered in Germantown, Maryland.

How the Company Makes Money

Senseonics primarily makes money by selling its Eversense CGM systems and related supplies and services through commercialization partnerships. Revenue is generated from sales of implantable glucose sensors, external transmitters, and other system components/consumables, along with associated commercial arrangements tied to distribution and marketing. A significant factor in its earnings is its partnership with Ascensia Diabetes Care, which commercializes (markets, sells, and distributes) Eversense in various markets under an agreement with Senseonics; the economics of this arrangement contribute to Senseonics’ revenue through product sales to/through the partner and/or other contract-based payments defined in the collaboration agreement. If additional material revenue streams beyond Eversense-related product sales and partner commercialization arrangements exist, null.

Senseonics Holdings Financial Statement Overview

Summary

Revenue growth re-accelerated in 2025 and gross margin rebounded sharply, but the business remains deeply unprofitable with persistently negative operating and free cash flow. Balance-sheet leverage looks more manageable in 2025, yet prior equity volatility and ongoing cash burn keep financial risk elevated.

Income Statement

Revenue growth re-accelerated in 2025 (up ~14% year over year) after being essentially flat in 2024, and gross margin improved sharply to ~45% in 2025 (from ~2% in 2024). However, profitability remains weak: 2023–2025 show deeply negative net margins (about -270% to -350% in 2023–2024 and ~-196% in 2025) with sizable operating losses, indicating the cost structure is still far ahead of the current revenue base. 2022 shows an outsized profit year, but results since then have reverted to heavy losses, reducing confidence in earnings consistency.

Balance Sheet

Leverage looks more manageable in 2025 with debt of ~$40.9M against equity of ~$61.0M (debt-to-equity ~0.67), and the company has a reasonable asset base (~$126.3M). That said, the balance sheet has been volatile: equity was negative in 2021, 2022, and 2024, which signals prior dilution/accumulated losses and increases financial risk. Returns on equity are currently negative (2025), consistent with ongoing losses.

Cash Flow

Cash generation remains the key pressure point. Operating cash flow is consistently negative (about -$56M to -$70M annually across 2020–2025), and free cash flow is also negative each year (about -$56M to -$71M), implying continued cash burn. While free cash flow improved modestly in 2025 versus 2024, the business still appears dependent on external funding until operating losses narrow materially.

Breakdown	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	35.26M	22.47M	22.39M	16.39M	13.68M
Gross Profit	15.76M	533.00K	3.09M	2.73M	-811.00K
EBITDA	-64.07M	-68.70M	-48.01M	161.81M	-284.51M
Net Income	-69.11M	-78.62M	-60.39M	142.12M	-302.47M
Balance Sheet
Total Assets	126.27M	100.44M	138.22M	177.67M	198.93M
Cash, Cash Equivalents and Short-Term Investments	94.03M	74.60M	109.46M	144.01M	129.91M
Total Debt	41.37M	61.05M	47.78M	75.38M	64.21M
Total Liabilities	65.22M	116.99M	64.77M	180.25M	384.46M
Stockholders Equity	61.05M	-16.55M	73.45M	-2.58M	-185.53M
Cash Flow
Free Cash Flow	-60.24M	-62.70M	-70.51M	-66.62M	-56.29M
Operating Cash Flow	-59.13M	-60.47M	-70.16M	-66.31M	-56.08M
Investing Cash Flow	-53.42M	32.84M	89.71M	26.88M	-148.75M
Financing Cash Flow	78.19M	26.83M	20.37M	41.76M	220.08M

Senseonics Holdings Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 6.34
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SENS, the sentiment is Negative. The current price of 6.34 is below the 20-day moving average (MA) of 7.01, below the 50-day MA of 7.18, and below the 200-day MA of 8.20, indicating a bearish trend. The MACD of -0.38 indicates Positive momentum. The RSI at 43.39 is Neutral, neither overbought nor oversold. The STOCH value of 65.95 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SENS.

Senseonics Holdings Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
DXCM	77 Outperform	$26.04B	30.97	32.44%	―	14.21%	5.66%
PODD	68 Neutral	$16.21B	80.92	17.36%	―	27.12%	-41.72%
LIVN	68 Neutral	$3.44B	-13.83	-21.49%	―	8.97%	-1024.86%
XTNT	66 Neutral	$81.20M	17.28	3.77%	―	16.88%	―
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
SENS	51 Neutral	$264.82M	-3.33	-104.17%	―	31.94%	36.59%
TNDM	45 Neutral	$1.63B	-7.22	-141.98%	―	17.87%	-57.03%

Senseonics Holdings Corporate Events

Senseonics Expands European Eversense Operations via Asset Agreements

On December 31, 2025, Senseonics entered into a master asset purchase agreement with Ascensia Diabetes Care to acquire assets related to the marketing, sale and distribution of the Eversense CGM product in the U.S., effective January 1, 2026, and to pursue additional asset purchases in several European markets. On March 12, 2026, the parties signed local asset purchase agreements for Italy, Germany, Spain and Sweden, under which Senseonics will acquire Ascensia’s related commercial assets and assume specified liabilities, with closings targeted by June 30, 2026, subject to regulatory and customary conditions, and supported by a transition services agreement aimed at ensuring continuity of logistics, IT, regulatory and operational functions during the handover.

The European local agreements provide for cash payments based on the net book value of the acquired assets and assumed liabilities in each country, aligning consideration with the underlying business transferred. To preserve and smoothly transition the Eversense operations in these markets, Ascensia will provide Senseonics with transition services in areas including logistics, payment and collections, tender contract performance, IT and systems migration, employee and operations support, and regulatory compliance generally through June 30, 2026, in return for agreed costs and service fees.

The most recent analyst rating on (SENS) stock is a Hold with a $6.00 price target. To see the full list of analyst forecasts on Senseonics Holdings stock, see the SENS Stock Forecast page.

Senseonics Reports Record 2025 Revenue and Growth Milestones

On January 12, 2026, Senseonics reported preliminary unaudited revenue of approximately $14.2 million for the fourth quarter of 2025 and $35.2 million for full-year 2025, representing year-over-year growth of 71% and about 57% respectively and marking the highest quarterly and annual revenue in the company’s history. The company’s cash, cash equivalents and restricted cash were estimated at about $94.3 million as of December 31, 2025, while its U.S. patient base more than doubled in the fourth quarter, up 103% from a year earlier, driven largely by direct-to-consumer marketing; operationally, Senseonics advanced its pipeline with FDA IDE approval and first patient enrollment for the pivotal Gemini sensor trial, initiated commercial use of pump partner Sequel’s twiist insulin delivery system compatible with Eversense 365, and executed agreements for Ascensia Diabetes Care to assume U.S. commercialization and distribution of Eversense starting January 1, 2026, developments that collectively strengthen its competitive position in the CGM market.

The most recent analyst rating on (SENS) stock is a Buy with a $15.00 price target. To see the full list of analyst forecasts on Senseonics Holdings stock, see the SENS Stock Forecast page.

Senseonics Acquires Eversense U.S. Assets, Reshapes Partnership

On December 31, 2025, Senseonics Holdings and its subsidiary Senseonics, Inc. signed a master asset purchase agreement with Ascensia Diabetes Care Holdings to acquire certain U.S. assets related to the marketing, selling and distribution of the Eversense CGM product, with the U.S. asset purchase closing on January 1, 2026 for approximately $1.1 million in cash, along with the assumption of related liabilities, including transferred contracts and certain employees. The parties also plan, subject to local agreements and regulatory and contractual closing conditions, to acquire additional commercial Eversense assets in Italy, Germany, Spain and Sweden by June 30, 2026, while an amended and restated collaboration and commercialization agreement effective January 1, 2026 terminates Ascensia’s U.S. marketing rights, makes its European rights non-exclusive, and shifts 100% of Eversense revenues in Europe to Senseonics, marking a strategic move to internalize global commercial operations; concurrently, PHC Holdings executive Koichiro Sato resigned from Senseonics’ board, and PHC signaled it does not currently intend to designate a new director despite retaining the right to do so.

The most recent analyst rating on (SENS) stock is a Hold with a $6.50 price target. To see the full list of analyst forecasts on Senseonics Holdings stock, see the SENS Stock Forecast page.